Compare GNE & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNE | TKNO |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.2M | 482.7M |
| IPO Year | 2011 | 2021 |
| Metric | GNE | TKNO |
|---|---|---|
| Price | $16.37 | $8.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 63.1K | ★ 254.4K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.83% | N/A |
| EPS Growth | ★ 95.65 | 43.86 |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $425,202,000.00 | $40,520,000.00 |
| Revenue This Year | N/A | $13.53 |
| Revenue Next Year | $1.86 | $14.01 |
| P/E Ratio | $30.41 | ★ N/A |
| Revenue Growth | N/A | ★ 7.35 |
| 52 Week Low | $12.69 | $1.91 |
| 52 Week High | $16.55 | $9.48 |
| Indicator | GNE | TKNO |
|---|---|---|
| Relative Strength Index (RSI) | 65.39 | 69.38 |
| Support Level | $13.47 | $4.87 |
| Resistance Level | $16.55 | $9.48 |
| Average True Range (ATR) | 0.33 | 0.50 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 84.88 | 81.27 |
Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.